April 7, 2008 - A recent BBC publication demonstrating the efficacy of Alpha-1 Antitrypsin in treating Type-1 Diabetes, shows a potential additional indication for AAT, Kamada's leading product. Kamada is a biopharmaceutical company developing, manufacturing and marketing specialty life-saving therapeutics.According to the BBC publication, the scientists demonstrated the ability to stop the on-going destruction of insulin-producing beta cells in mice using a combination of three drugs, although they were unable to regenerate the cells. However, when they added an extra ingredient - an enzyme called Alpha 1 Antitrypsin - a significant rise in the number of beta cells was seen... Kamada's Press Release -
